Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials
- Resource Type
- Article
- Source
- In
Contemporary Clinical Trials Communications June 2018 10:62-76 - Subject
- Language
- ISSN
- 2451-8654